How CAR-T Cell Therapy Works to Fight Cancer

Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in immunotherapy, utilizing gene editing to reprogram a patient’s own immune system to combat cancer. This cell-based gene therapy modifies T lymphocytes—a type of white blood cell—to express a lab-made protein called a chimeric antigen receptor, which enables these cells to identify and destroy cancerous cells more effectively.

The process functions by introducing a new gene into T cells, transforming them into specialized cancer-fighting machines. In a healthy immune system, T cells use receptors to find antigens, which are proteins on the surface of foreign cells. Because the relationship between antigens and receptors acts like a lock and key, cancer cells can often evade detection if the immune cells lack the specific receptor required to bind to the cancer’s antigens.

Application in Blood Cancers

Currently, CAR T-cell therapy is primarily used to treat certain types of blood cancers, particularly when other treatments have proven ineffective or when the cancer returns. It has been used to treat B-cell malignancies and multiple myeloma by redirecting activated T cells toward tumor cells that express BCMA or CD19.

The impact of this personalized therapy varies by patient. In some instances, the treatment can completely eradicate the disease in people with very advanced cancer, while in other cases, it helps patients live longer.

Technical Challenges and Solid Tumors

Despite its success in hematological malignancies, applying CAR T-cell therapy to solid tumors and certain other blood cancers, such as acute myeloid leukemia (AML), presents significant technical hurdles.

A primary challenge in treating AML is the lack of an ideal target antigen. AML cells often share surface antigens with healthy hematopoietic stem and progenitor cells (HSPCs). If a therapy targets antigens present on both the cancer cells and healthy stem cells, it can lead to life-threatening on-target/off-tumor toxicities, including prolonged myeloablation.

the tumor microenvironment in AML is immunosuppressive, which can negatively impact the overall immune response and hinder the effectiveness of the engineered T cells.

The Shift Toward Off-the-Shelf Solutions

While traditional CAR T-cell therapy is a personalized process requiring the extraction and modification of a patient’s own cells, research is moving toward designing treatments that work off-the-shelf. Such innovations aim to create a more scalable and accessible treatment model, particularly for solid tumor cancers.

Further research is also exploring methods to create cancer-fighting immune cells directly within the body, potentially removing the need for external lab-based genetic engineering of cells.

• CAR T-cell therapy is a form of immunotherapy and cell-based gene therapy.
• It is currently an option for some blood cancers when other treatments fail.
• The therapy works by adding a lab-made gene to T cells to help them detect and kill cancer.
• Challenges remain for solid tumors and AML due to antigen overlap with healthy cells.